

**Corp. Off.:** 502, Kanakia Atrium - 2,  
Next to Courtyard Marriott Hotel,  
Andheri Kurla Road, Andheri (East),  
Mumbai - 400 093 (India)  
Ph.: + 91 22 61933100 Fax : +91 22 61933114

13<sup>th</sup> August, 2015

**BSE Limited**

Phiroze Jeejeebhoy Towers  
Dalal Street  
Mumbai 400 001

**National Stock Exchange of India Ltd.**

Exchange Plaza, C-1, Block G  
Bandra-Kurla Complex  
Bandra(E), Mumbai 400 051.

Security ID/Symbol: **BROOKS**

Sub: **Outcome of the Board Meeting held on 13<sup>th</sup> August, 2015**


Dear Sirs,

Further to our letter dated 5<sup>th</sup> August, 2015, we wish to inform you that the Board of Directors at its meeting held today has, inter alia, approved the Unaudited Financial Results of the Company for the 1<sup>st</sup> quarter ended 30<sup>th</sup> June, 2015. The Audit Committee reviewed the Unaudited Financial Results at its Meeting held earlier today which have been subjected to a limited review by the Statutory Auditors. The Statement of Unaudited Financial Results, together with the Limited Review Report is attached.

Yours faithfully,

For Brooks Laboratories Limited

  
Rajesh Mahajan  
Managing Director



Encl: a/a

# **SGCO & Co.**

**Chartered Accountants**


## **The Board of Directors Brooks Laboratories Limited**

1. We have reviewed the results of Brooks Laboratories Limited (the "Company"), for the quarter ended on June 30, 2015 which are included in the accompanying 'Unaudited Financial Results for the quarter ended on June 30, 2015 except for the disclosures regarding 'Public Shareholding' and 'Promoter and Promoter Group Shareholding' which have been traced from disclosures made by the Management but have neither been reviewed nor been audited by us. The Statement has been prepared by the Company pursuant to Clause 41 of the Listing Agreement with the Stock Exchanges in India. This Statement is the responsibility of the Company's management and has been approved by the board of Directors. Our responsibility is to issue a report on the Statement based on our review.
2. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement.
3. A review is limited primarily to inquiries of company personnel and analytical procedure applied to financial data and thus provides less assurance than an audit. We have not performed an audit and, accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the Statement has not been prepared in all material respects in accordance with the Accounting Standards specified under the Companies Act, 1956 (which are deemed to be applicable as per section 133 of the Companies Act, 2013, read with Rule 7 of the Companies (Accounts) Rules, 2014) and other recognized accounting practices and policies, and has not disclosed the information required to be disclosed in terms of Clause 41 of the Listing Agreement including the manner in which it is to be disclosed, or that it contains any material misstatement.

**For S G C O & Co.**

Chartered Accountants

Firm Reg. No : 112081W

  
**Suresh Murarka**

Partner

Mem No.: 44739



Place: Mumbai

Date: 13<sup>th</sup> August, 2015

4A, Kaledonia-HDIL,  
2<sup>nd</sup> Floor, Sahar Road,  
Near Andheri Station,  
Andheri (East),  
Mumbai - 400 069. India

Tel.: +91 22 6625 6363  
Fax: +91 22 6625 6364  
E-mail: [info@sgco.co.in](mailto:info@sgco.co.in)  
[www.sgco.co.in](http://www.sgco.co.in)

**BROOKS LABORATORIES LIMITED**  
**Regd Office: Village Kishanpura, Nalagarh Road, Baddi, Dist. Solan H.P.-174101**  
**CIN NO: L24232HP2002PLC000267**

Tel No : +91 1795 654001/02/03, Fax No :+91 1795 236939, E-mail : investors@brookslabs.net, Website: www.brookslabs.net

**Unaudited Standalone Financial Results for the Quarter Ended June 30, 2015**

**PART I**

|                                                                                                            |  | (Rs. In Lacs)   |                 |                 |                 |
|------------------------------------------------------------------------------------------------------------|--|-----------------|-----------------|-----------------|-----------------|
| Particulars                                                                                                |  | Quarter Ended   |                 |                 | Year Ended      |
|                                                                                                            |  | 30.06.2015      | 31.03.2015      | 30.06.2014      | 31.03.2015      |
|                                                                                                            |  | (Unaudited)     | (Audited)       | (Unaudited)     | (Audited)       |
| <b>1 Income from operations</b>                                                                            |  |                 |                 |                 |                 |
| (a) Net sales (Net of excise duty)                                                                         |  | 1,797.71        | 2,351.43        | 1,646.11        | 8,521.33        |
| <b>Total income from operations (net)</b>                                                                  |  | <b>1,797.71</b> | <b>2,351.43</b> | <b>1,646.11</b> | <b>8,521.33</b> |
| <b>2 Expenses</b>                                                                                          |  |                 |                 |                 |                 |
| (a) Cost of materials consumed                                                                             |  | 1,259.01        | 1,669.66        | 1,205.15        | 6,041.14        |
| (b) Changes in inventories of finished goods & work-in-progress                                            |  | 29.59           | (25.24)         | 34.76           | 23.61           |
| (d) Employee benefits expense                                                                              |  | 131.04          | 120.19          | 109.96          | 473.21          |
| (e) Depreciation and amortisation expense                                                                  |  | 28.04           | 26.44           | 28.21           | 110.36          |
| (f) Other Expenses                                                                                         |  | 214.61          | 383.05          | 185.39          | 1,297.27        |
| <b>Total expenses</b>                                                                                      |  | <b>1,662.29</b> | <b>2,174.10</b> | <b>1,563.47</b> | <b>7,945.59</b> |
| <b>3 Profit / (Loss) from operations before other income, finance costs and exceptional items (1-2)</b>    |  | <b>135.42</b>   | <b>177.33</b>   | <b>82.64</b>    | <b>575.74</b>   |
| 4 Other income                                                                                             |  | 36.42           | 37.18           | 68.52           | 225.17          |
| <b>5 Profit / (Loss) from ordinary activities before finance costs and exceptional items (3 + 4)</b>       |  | <b>171.84</b>   | <b>214.51</b>   | <b>151.16</b>   | <b>800.91</b>   |
| 6 Finance costs                                                                                            |  | 6.86            | 11.16           | 2.23            | 44.34           |
| <b>7 Profit / (Loss) from ordinary activities after finance costs but before exceptional items (5 - 6)</b> |  | <b>164.98</b>   | <b>203.35</b>   | <b>148.93</b>   | <b>756.57</b>   |
| 8 Exceptional items / Prior period items                                                                   |  | -               | 68.29           | -               | 278.47          |
| <b>9 Profit / (Loss) from ordinary activities before tax (7 - 8)</b>                                       |  | <b>164.98</b>   | <b>271.64</b>   | <b>148.93</b>   | <b>1,035.04</b> |
| 10 Tax expense (Refer Note 4)                                                                              |  | 13.60           | 37.39           | (4.57)          | 88.32           |
| <b>11 Net Profit / (Loss) from ordinary activities after tax (9-10)</b>                                    |  | <b>151.38</b>   | <b>234.25</b>   | <b>153.50</b>   | <b>946.72</b>   |
| 12 Extraordinary items                                                                                     |  | -               | -               | -               | -               |
| <b>13 Net Profit / (Loss) for the period (11 + 12)</b>                                                     |  | <b>151.38</b>   | <b>234.25</b>   | <b>153.50</b>   | <b>946.72</b>   |
| 14 Paid-up equity share capital<br>(Face Value Rs.10/- per share)                                          |  | 1,618.64        | 1,618.64        | 1,618.64        | 1,618.64        |
| 15 Reserve excluding Revaluation Reserves as per balance sheet of previous accounting year                 |  | -               | -               | -               | 9,523.04        |
| <b>16.i Earnings per share (before extraordinary items) (of Rs.10/- each) (not annualised):</b>            |  |                 |                 |                 |                 |
| (a) Basic -in Rs.                                                                                          |  | 0.94            | 1.45            | 0.95            | 5.85            |
| (b) Diluted- in Rs.                                                                                        |  | 0.94            | 1.45            | 0.95            | 5.85            |
| <b>16.ii Earnings per share (after extraordinary items) (of Rs.10/- each) (not annualised):</b>            |  |                 |                 |                 |                 |
| (a) Basic -in Rs.                                                                                          |  | 0.94            | 1.45            | 0.95            | 5.85            |
| (b) Diluted- in Rs.                                                                                        |  | 0.94            | 1.45            | 0.95            | 5.85            |
| <b>PART- II</b>                                                                                            |  |                 |                 |                 |                 |
| <b>A PARTICULARS OF SHAREHOLDING</b>                                                                       |  |                 |                 |                 |                 |
| <b>1 Public shareholding</b>                                                                               |  |                 |                 |                 |                 |
| -Number of shares                                                                                          |  | 6,374,473       | 6,374,473       | 6,374,473       | 6,374,473       |
| -Percentage of shareholding                                                                                |  | 39.38%          | 39.38%          | 39.38%          | 39.38%          |
| <b>2 Promoters and Promoter Group Shareholding</b>                                                         |  |                 |                 |                 |                 |
| a) Pledged / Encumbered                                                                                    |  |                 |                 |                 |                 |
| -Number of shares                                                                                          |  | -               | -               | -               | -               |
| -Percentage of shares (as a % of the total shareholding of promoter and promoter group)                    |  | -               | -               | -               | -               |
| -Percentage of shares (as a % of the total share capital of the company)                                   |  | -               | -               | -               | -               |
| b) Non - encumbered                                                                                        |  |                 |                 |                 |                 |
| -Number of shares                                                                                          |  | 9,811,949       | 9,811,949       | 9,811,949       | 9,811,949       |
| -Percentage of shares (as a % of the total shareholding of promoter and promoter group)                    |  | 100%            | 100%            | 100%            | 100%            |
| -Percentage of shares (as a % of the total share capital of the company)                                   |  | 60.62%          | 60.62%          | 60.62%          | 60.62%          |



---

**B INVESTOR COMPLAINTS FOR QUARTER ENDED JUNE 30, 2015**  
Opening Balance : Nil, Received and Resolved: Nil, Closing Balance: Nil

---


**Notes :**

- 1 The above results were reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on 13th August, 2015.
- 2 The figures of the quarter ended March 31, 2015 are the balancing figures between audited financial results for the year ended March 31, 2015 and the published results for the nine months ended December 31, 2014.
- 3 The Company has raised an amount of Rs. 6300.00 Lacs through a public issue of equity shares in the year 2011-12. The said proceeds has been fully utilised during the current quarter in terms of the offer document for the purpose of setting up a new manufacturing unit at Gujarat, general corporate purpose and meeting IPO expenses.
- 4 Tax expense includes Current Tax, Mat Credit Entitlement and Deferred Tax.
- 5 The Company is mainly engaged in the business of "Pharmaceutical Formulations" and there is no other reportable business segment as per Accounting Standard (AS-17) as notified under the Companies (Accounting Standards) Rules, 2006.
- 6 Figures of the previous period / year have been reclassified / regrouped wherever necessary.

For and on behalf of the Board

Date : August 13, 2015

Place : Mumbai

  
Rajesh Mahajan  
DIN No. : 02000634  
Managing Director

